title: Phase I study of topotecan and radiation therapy in advanced cervical cancer.
abstract: OBJECTIVE
  The goal of this study was to determine the maximal tolerated dose (MTD) of topotecan given with external-beam radiotherapy in advanced cervical cancer.
  
  
  METHODS
  A prospective Phase I trial of topotecan given with standard external-beam radiotherapy was performed in patients with advanced squamous cell carcinoma of the cervix. Patients were treated with a starting dose of 0.5 mg/m(2) and escalated by 0.25 mg/m(2). Nine patients were treated. Hematologic and nonhematologic toxicity were measured.
  
  
  RESULTS
  Patients were treated with 1.0 mg/m(2) daily for 5 days on Days 1-5 and 22-26 concomitantly with radiotherapy without significant toxicity. Grade III anemia in one case and Grade II leukopenia in two cases were seen in the three patients at this dose level. Dose-limiting toxicity was not reached.
  
  
  CONCLUSIONS
  Topotecan can be safely administered at a dose of 1.0 mg/m(2) during external-beam radiotherapy for advanced cervical cancer.
authors.affiliation: Division of Gynecologic Oncology, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. charles.dunton@mail.tju.edu
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Dunton
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: King
authors.forename: Julia
authors.initials: J
authors.lastname: Neufeld
authors.forename: Jorge
authors.initials: J
authors.lastname: Tolosa
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Perez
authors.forename: Andres
authors.initials: A
authors.lastname: Avila
authors.forename: Kelly
authors.initials: K
authors.lastname: Underhill
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced / Q000209:etiology; D006801:Humans; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019772:Topotecan / Q000009:adverse effects* / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D019772:Topotecan